Literature DB >> 17323045

[Development of a screening tool for migraine prophylaxis].

A Wissmann1, A Feuersenger, A Gendolla, U Reuter, A Straube, S Evers, A May, A Peikert, V Pfaffenrath, H Staudenmayer, H-C Diener.   

Abstract

The aim of the present study was to develop a screening tool to aid non-headache specialists, like general practitioners, in deciding whether migraine prophylaxis in the individual migraine patient is useful or not. The first step was the development of a questionnaire, consisting of 10 items, which was filled in by 132 migraineurs who called on neurologists or headache experts. Independently, the physicians filled in another questionnaire to answer the question of whether they decided to prescribe migraine prophylaxis and if they had, to give their reasons for doing so. Using logistic regression analysis, we identified the three questions which had the most influence on the decision regarding prophylaxis in the data set. As results, we identified the following three questions: 1. Do you suffer from migraine on more than 3 days/month? 2. Do you have to rest in bed while experiencing a migraine attack? 3. Do you have to take medication against migraine on more than 5 days/month? Validation of this reduced questionnaire is currently ongoing and involves 150 migraine patients of general practitioners.

Entities:  

Mesh:

Year:  2007        PMID: 17323045     DOI: 10.1007/s00482-007-0529-4

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  12 in total

1.  Multispecialty consensus on diagnosis and treatment of headache.

Authors:  S D Silberstein; J Rosenberg
Journal:  Neurology       Date:  2000-04-25       Impact factor: 9.910

2.  Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  S D Silberstein
Journal:  Neurology       Date:  2000-09-26       Impact factor: 9.910

3.  Cost of migraine and other headaches in Europe.

Authors:  J Berg; L J Stovner
Journal:  Eur J Neurol       Date:  2005-06       Impact factor: 6.089

4.  Long-term results of migraine prophylaxis with flunarizine and beta-blockers.

Authors:  C Wöber; C Wöber-Bingöl; G Koch; P Wessely
Journal:  Cephalalgia       Date:  1991-12       Impact factor: 6.292

5.  Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period.

Authors:  Chelsea A Meskunas; Stewart J Tepper; Alan M Rapoport; Fred D Sheftell; Marcelo E Bigal
Journal:  Headache       Date:  2006-05       Impact factor: 5.887

6.  Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials.

Authors:  G Bussone; H-C Diener; J Pfeil; S Schwalen
Journal:  Int J Clin Pract       Date:  2005-08       Impact factor: 2.503

7.  A self-administered screener for migraine in primary care: The ID Migraine validation study.

Authors:  R B Lipton; D Dodick; R Sadovsky; K Kolodner; J Endicott; J Hettiarachchi; W Harrison
Journal:  Neurology       Date:  2003-08-12       Impact factor: 9.910

8.  [Prophylactic drug management of migraine].

Authors:  H Göbel; A Heinze
Journal:  Schmerz       Date:  2002-06       Impact factor: 1.107

9.  Epidemiology of headache and childhood migraine in an urban general practice using Ad Hoc, Vahlquist and IHS criteria.

Authors:  M J Mortimer; J Kay; A Jaron
Journal:  Dev Med Child Neurol       Date:  1992-12       Impact factor: 5.449

10.  The epidemiology of headache in Germany: a nationwide survey of a representative sample on the basis of the headache classification of the International Headache Society.

Authors:  H Göbel; M Petersen-Braun; D Soyka
Journal:  Cephalalgia       Date:  1994-04       Impact factor: 6.292

View more
  1 in total

Review 1.  [Alternatives to beta blockers in preventive migraine treatment].

Authors:  S Evers
Journal:  Nervenarzt       Date:  2008-10       Impact factor: 1.214

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.